Seoulin Bioscience Co.Ltd (038070) - Total Liabilities

Latest as of December 2025: ₩32.75 Billion KRW ≈ $22.19 Million USD

Based on the latest financial reports, Seoulin Bioscience Co.Ltd (038070) has total liabilities worth ₩32.75 Billion KRW (≈ $22.19 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Seoulin Bioscience Co.Ltd - Total Liabilities Trend (2013–2025)

This chart illustrates how Seoulin Bioscience Co.Ltd's total liabilities have evolved over time, based on quarterly financial data. See Seoulin Bioscience Co.Ltd (038070) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.

Seoulin Bioscience Co.Ltd Competitors by Total Liabilities

The table below lists competitors of Seoulin Bioscience Co.Ltd ranked by their total liabilities.

Company	Country	Total Liabilities
ANAX Metals Ltd AU:ANX	Australia	AU$22.55 Million
Aztec Minerals Corp V:AZT	Canada	CA$1.30 Million
Shaftesbury Capital PLC LSE:SHC	UK	GBX1.31 Billion
Black Iron Inc. TO:BKI	Canada	CA$4.28 Million
Softing AG XETRA:SYT	Germany	€50.05 Million
Next Science Ltd AU:NXS	Australia	AU$10.02 Million
Shanghai Lingyun Industries Development Co Ltd SHG:900957	China	$423.71 Million
Desert Gold Ventures Inc V:DAU	Canada	CA$226.73K

Liability Composition Analysis (2013–2025)

This chart breaks down Seoulin Bioscience Co.Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Seoulin Bioscience Co.Ltd (038070) market capitalisation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	2.27	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.39	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.28	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Seoulin Bioscience Co.Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Seoulin Bioscience Co.Ltd (2013–2025)

The table below shows the annual total liabilities of Seoulin Bioscience Co.Ltd from 2013 to 2025.

Year	Total Liabilities	Change
2025-12-31	₩32.75 Billion ≈ $22.19 Million	+85.72%
2024-12-31	₩17.63 Billion ≈ $11.95 Million	-43.19%
2023-12-31	₩31.04 Billion ≈ $21.03 Million	-39.24%
2022-12-31	₩51.08 Billion ≈ $34.62 Million	-17.21%
2021-12-31	₩61.71 Billion ≈ $41.82 Million	+236.70%
2020-12-31	₩18.33 Billion ≈ $12.42 Million	-12.73%
2019-12-31	₩21.00 Billion ≈ $14.23 Million	+20.72%
2018-12-31	₩17.39 Billion ≈ $11.79 Million	-11.00%
2017-12-31	₩19.54 Billion ≈ $13.24 Million	+9.39%
2016-12-31	₩17.87 Billion ≈ $12.11 Million	-14.12%
2015-12-31	₩20.80 Billion ≈ $14.10 Million	+18.36%
2014-12-31	₩17.57 Billion ≈ $11.91 Million	-6.62%
2013-12-31	₩18.82 Billion ≈ $12.75 Million	--

About Seoulin Bioscience Co.Ltd

KQ:038070 Korea Biotechnology

Market Cap

$30.03 Million

₩44.31 Billion KRW

Market Cap Rank

#23814 Global

#1629 in Korea

Share Price

₩5020.00

Change (1 day)

-3.09%

52-Week Range

₩4820.00 - ₩7990.00

All Time High

₩36786.63